apecotrep (BI 764198) / Boehringer Ingelheim, Aurobac Therapeutics - LARVOL DELTA

Angiotensin system modulation in focal segmental glomerulosclerosis: pharmacological basis and clinical implications. (PubMed, Expert Opin Pharmacother) - "Nonetheless, it remains a cornerstone of care.Emerging therapies, including dual AT1/endothelin-A antagonism (sparsentan) and podocyte-targeted approaches (apecotrep), show promising proteinuria reductions but have not yet demonstrated clear benefits on hard renal outcomes. Biomarker-driven strategies (e.g. anti-nephrin antibodies, APOL1 genotyping) may enable more tailored treatment, although their clinical impact remains to be established."

Journal • Review • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Nephrology • Renal Disease

Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Glonova Pharma Co., Ltd | Trial completion date: Jan 2027 ➔ Aug 2028 | Trial primary completion date: Nov 2026 ➔ May 2028

Trial completion date • Trial primary completion date

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - P3 | N=286 | Recruiting | Sponsor: Boehringer Ingelheim | N=103 ➔ 286

Enrollment change • Trial initiation date • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • TRPC6

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - P3 | N=286 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • TRPC6

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - P3 | N=286 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Dec 2029 ➔ Jan 2029 | Trial primary completion date: Nov 2029 ➔ Dec 2028

Trial completion date • Trial primary completion date • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • TRPC6

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease • TRPC6

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease (clinicaltrials.gov) - P2 | N=132 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Pan tumor • Nephrology • Renal Disease • CST3

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Aug 2023 ➔ Feb 2024 | Trial primary completion date: Jul 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - P3 | N=103 | Recruiting | Sponsor: Boehringer Ingelheim | N=76 ➔ 103

Enrollment change • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • TRPC6

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - P2 | N=67 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease • TRPC6

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P2 trial • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - P3 | N=286 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P3 trial • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease (clinicaltrials.gov) - P2 | N=132 | Not yet recruiting | Sponsor: Boehringer Ingelheim | N=60 ➔ 132

Enrollment change • Pan tumor • Nephrology • Renal Disease • CST3

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - P3 | N=286 | Not yet recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Mar 2030 ➔ Dec 2029 | Trial primary completion date: Feb 2030 ➔ Nov 2029

Trial completion date • Trial primary completion date • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Feb 2024 ➔ Feb 2025 | Trial primary completion date: Jan 2024 ➔ Jan 2025

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - P3 | N=61 | Recruiting | Sponsor: Boehringer Ingelheim | N=38 ➔ 61

Enrollment change • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • TRPC6

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - P3 | N=105 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • TRPC6

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P2 trial • Pan tumor • Nephrology • Renal Disease • CST3

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - P3 | N=286 | Recruiting | Sponsor: Boehringer Ingelheim | N=105 ➔ 286

Enrollment change • Trial initiation date • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • TRPC6

1434-0027: PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease (clinicaltrialsregister.eu) - P1/2 | N=20 | Not yet recruiting | Sponsor: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

New P1/2 trial • Pan tumor • Nephrology • Renal Disease

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 764198 in the Blood (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion

A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 764198 in the Blood (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Boehringer Ingelheim

Trial initiation date

1434-0017: A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) (clinicaltrialsregister.eu) - P2/3 | N=38 | Not yet recruiting | Sponsor: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

New P2/3 trial • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • TRPC6